scholarly journals Impact of beta blockers on survival outcomes in ovarian cancer: A nationwide population-based cohort study

2019 ◽  
Vol 154 ◽  
pp. 226-227
Author(s):  
M.H. Baek ◽  
Y.H. Park
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Beta Blockers ◽  
Population Based ◽  
Survival Outcomes

scholarly journals Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study

2018 ◽  
Vol 29 (6) ◽  
Author(s):  
Min-Hyun Baek ◽  
Dae-Yeon Kim ◽  
Seon Ok Kim ◽  
Ye-Jee Kim ◽  
Young-Han Park
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Beta Blockers ◽  
Population Based ◽  
Survival Outcomes

Abstract 12444: Outcomes After Starting Beta-Blockade Within a Clinically Sensible Period Before Major Elective Noncardiac Surgery

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Duminda N Wijeysundera ◽  
Dennis T Ko ◽  
Harindra C Wijeysundera ◽  
Lingsong Yun ◽  
W. Scott Beattie
Keyword(s):  
Cohort Study ◽  
Beta Blockers ◽  
Risk Index ◽  
Cardiac Risk ◽  
Population Based ◽  
Noncardiac Surgery ◽  
Beta Blockade ◽  
Matched Cohort ◽  
Post Surgery ◽  
Median Daily Dose

INTRODUCTION: Guidelines recommend that perioperative beta-blockade be started days to weeks before surgery. Nonetheless, all randomized trials except for the controversial DECREASE trials started treatment ≤1 day before surgery, while most observational studies did not distinguish between long-term beta-blockade versus beta-blockers started for perioperative reasons. We thus conducted a population-based cohort study of the effectiveness of beta-blockade started within a clinically sensible period (8-60 days) before surgery. METHODS: Following research ethics approval, we conducted a cohort study of patients (≥66 years) who underwent major elective noncardiac surgery from 2003 and 2012 in Ontario, Canada. Propensity-score methods were used to form a matched cohort that reduced important differences between patients who started beta-blockers 8-60 days before surgery versus controls (no beta-blockers within 1 year before surgery). We measured the association of beta-blockade with 30-day (death, MI, stroke) and 1-year (death) outcomes post-surgery. Subgroup analyses were performed based on Revised Cardiac Risk Index class and history of prior CAD. RESULTS: The cohort included 4268 beta-blocked patients and 154,357 controls. Metoprolol (median daily dose 50 mg) was prescribed to 36% of beta-blocked patients, atenolol (median 25 mg) to 26%, and bisoprolol (median 5 mg) to 37%. In the matched cohort (n=8492), beta-blockade was not associated with death (RR 0.96; CI 0.70-1.32), MI (RR 0.92; CI 0.72-1.17), and stroke (RR 1.31; CI 0.68-2.52) at 30-days, or death at 1-year (Figure). Associations with outcomes did not differ significantly across subgroups. CONCLUSIONS: Outcomes were not altered in patients who start perioperative beta-blockade within a clinically sensible period before surgery. A large randomized trial is needed to determine if the continued use of perioperative beta-blockade in clinical practice is justified.

scholarly journals Use of Fertility Drugs and Risk of Ovarian Cancer: Danish Population Based Cohort Study

2009 ◽  
Vol 64 (6) ◽  
pp. 390-391 ◽  
Author(s):  
Allan Jensen ◽  
Heidi Sharif ◽  
Kirsten Frederiksen ◽  
Susanne Krüger Kjær
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Population Based ◽  
Danish Population ◽  
Fertility Drugs

scholarly journals Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study

2019 ◽  
Vol 34 (11) ◽  
pp. 1093-1101 ◽  
Author(s):  
Frida E. Lundberg ◽  
Anna L. V. Johansson ◽  
Kenny Rodriguez-Wallberg ◽  
Kristina Gemzell-Danielsson ◽  
Anastasia N. Iliadou
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Assisted Reproductive Technology ◽  
Population Based ◽  
Reproductive Technology ◽  
Borderline Tumors

scholarly journals Subsequent Development of Epithelial Ovarian Cancer After Ovarian Surgery for Benign Ovarian Tumor: A Population-Based Cohort Study

2020 ◽  
Vol Volume 12 ◽  
pp. 637-649 ◽  
Author(s):  
Chen-Yu Huang ◽  
Wen-Hsun Chang ◽  
Hsin-Yi Huang ◽  
Chao-Yu Guo ◽  
Yiing-Jenq Chou ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Epithelial Ovarian Cancer ◽  
Ovarian Tumor ◽  
Subsequent Development ◽  
Population Based ◽  
Benign Ovarian Tumor ◽  
Ovarian Surgery

scholarly journals Pharmacological Treatment After Acute Coronary Syndrome: Baseline Clinical Characteristics and Sex Differences in a Population-Based Cohort Study.

2020 ◽  
Author(s):  
Gerard Sotorra-Figuerola ◽  
Dan Ouchi ◽  
Ana García-Sangenís ◽  
Maria Giner-Soriano ◽  
Rosa Morros
Keyword(s):  
Acute Coronary Syndrome ◽  
Cohort Study ◽  
Secondary Prevention ◽  
Clinical Characteristics ◽  
Beta Blockers ◽  
Study Groups ◽  
Population Based ◽  
First Episode ◽  
Source Information ◽  
Coronary Syndrome

Abstract Background: Cardiovascular disease remains the most common cause of death worldwide. Some differences between sexes in secondary prevention pharmacological therapies after an acute coronary syndrome (ACS) have been described, being women less likely to be treated. The aim was to to describe baseline socio-demographic and clinical characteristics and drugs prescribed for secondary prevention after a first episode of ACS in a Primary Health Care cohort population in Catalonia (Spain) and to assess differences between sexes.Methods: Population-based observational cohort study of patients with a first episode of ACS during 2009-2016. Data source: Information System for Research in Primary Care (SIDIAP) database. Results: There were 8,071 patients included, 71.3% of them were men and 80.2% had an acute myocardial infarction (AMI). Their mean age was 65.3, being older the women than the men. The most frequent comorbidities were hypertension, dyslipidaemia and diabetes and they were more common in women. Antiplatelets (91.3%) and statins (85.7%) were the study drugs most prescribed. The uses of all comedications were significantly higher in women, except for nitrates. The combination of four study groups was initially prescribed in 47.7% of patients and combination of beta-blockers, statins and antiplatelets was prescribed in 18.4%. More men than women received all recommended pharmacological groups.Conclusion: Women were older, had more comorbidities and received more comedication. Most patients were treated with a combination of four or three study drugs for secondary prevention. Men initiated more treatments for secondary prevention and dual antiplatelet therapy than women.

scholarly journals Impact of metformin on survival outcome in ovarian cancer: a nationwide population-based cohort study

2021 ◽  
Vol 32 ◽  
Author(s):  
Jeong-Yeol Park ◽  
Myong Cheol Lim ◽  
Min-Hyun Baek ◽  
Young-Han Park ◽  
Seonok Kim
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Population Based ◽  
Survival Outcome
Sign in / Sign up

Export Citation Format

Share Document